.Nature Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a mean consequence of 11 months, patients with metastatic stomach cysts who obtained biomarker-matched therapies based upon distributing tumor DNA profiling revealed a better scientific advantage than those getting incomparable therapy.